Selective Brain Hypothermia in the Comprehensive Rehabilitation of Patients with Chronic Consciousness Disorders

Aim: to evaluate clinical effectiveness of selective hypothermia of cerebral cortex for the recovery of awareness in patients with chronic disorders of consciousness (CDC).   Material and methods. 111 patients with CDC 30 and more days after a cerebral event (ischemic or hemorrhagic stroke, brain injury) were included in the study. Exclusion criteria were anoxic brain injury (sequelae of a prolonged asystole or asphyxia), active sepsis, arrhythmia, baseline hypothermia (body temperature lower than 35.5 °С). Experimental group included 60 patients, of them 39 patients were in a vegetative state (VS), 21 patients exhibited patterns of minimally conscious state (MCS). Control group incluted 51 patients, of them 32 patients were in VS and 19 patients were in MCS. Patients in the experimental group received 10 sessions (120 minutes each) of selective brain hypothermia (SBH) during the 14-days follow-up period. Patients of both groups received standard identical neurological treatment and rehabilitation procedures. Patients in the control group did not undergo brain hypothermia. The induction of SBH involved cooling of the whole surface of the craniocerebral area of scalp using special helmets. The temperature of the internal surface of the helmet was 3–7 °С. Temperature of the frontal lobes of the cortex was monitored with non-invasive microwave radiothermometry, axillary temperature was also registered. The level of consciousness was evaluated using «Coma Recovery Scale-Revised» (CRS-R) scale.   Results. 120-minutes long SBH session reduced the temperature of the frontal lobes of the cerebral cortex by 2.4–3.1 °С with no impact on the axillary temperature. Evaluation using CRS-R revealed improvement in all studied functions (auditory, visual, motor, oromotor, communication, arousal) in patients in the experimental group after 10 SBH sessions. Level of consciousness in patients from the experimental group in VS increased from 4.5 ± 0.33 to 8.7 ± 0.91 points (P < 0.001), for patients in MCS from 11.3 ± 1.0 to 18.2 ± 0.70 (P < 0.001) points. In the control group, scores of patients in VS rose from 4.3 ± 0.37 to 6.8 ± 0.49 (P < 0.001) points with the most significant changes in auditory and visual functions (P<0.001). In the control group of patients in MCS the oromotor function improved (P < 0.05), overall CRS-R scores changed insignificantly from 9.1 ± 0.57 to 10.1 ± 0.86 (P < 0.1). The best outcome (CRS-R > 19 points) was seen in patients from the experimental group [6 in VS (15.4 %) and 8 in MCS (31.8 %)]. In the control group, the best results did not exceed 10 points for the patents in VS, while 4 patients in MCS (21 %) reached 12–16 scores. During 30-day follow-up period of hospitalization after the SBH sessions mortality rate was 10 % (6 patients) in the experimental group and 21.6% (11 patients) in the control group.   Conclusion. Patients with CDC could benefit from serial SBH sessions performed as a part of comprehensive treatment and rehabilitation strategy. We suggest that selective reduction of frontal lobe temperature improves neurogenesis, neuronal regeneration, and neuroplasticity

Селективная гипотермия коры больших полушарий в комплексной реабилитации пациентов с хроническими нарушениями сознания

   Aim: to evaluate clinical effectiveness of selective hypothermia of cerebral cortex for the recovery of awareness in patients with chronic disorders of consciousness (CDC).   Material and methods. 111 patients with CDC 30 and more days after a cerebral event (ischemic or hemorrhagic stroke, brain injury) were included in the study. Exclusion criteria were anoxic brain injury (sequelae of a prolonged asystole or asphyxia), active sepsis, arrhythmia, baseline hypothermia (body temperature lower than 35.5 °С). Experimental group included 60 patients, of them 39 patients were in a vegetative state (VS), 21 patients exhibited patterns of minimally conscious state (MCS). Control group incluted 51 patients, of them 32 patients were in VS and 19 patients were in MCS. Patients in the experimental group received 10 sessions (120 minutes each) of selective brain hypothermia (SBH) during the 14-days follow-up period. Patients of both groups received standard identical neurological treatment and rehabilitation procedures. Patients in the control group did not undergo brain hypothermia. The induction of SBH involved cooling of the whole surface of the craniocerebral area of scalp using special helmets. The temperature of the internal surface of the helmet was 3–7 °С. Temperature of the frontal lobes of the cortex was monitored with non-invasive microwave radiothermometry, axillary temperature was also registered. The level of consciousness was evaluated using «Coma Recovery Scale-Revised» (CRS-R) scale.   Results. 120-minutes long SBH session reduced the temperature of the frontal lobes of the cerebral cortex by 2.4–3.1 °С with no impact on the axillary temperature. Evaluation using CRS-R revealed improvement in all studied functions (auditory, visual, motor, oromotor, communication, arousal) in patients in the experimental group after 10 SBH sessions. Level of consciousness in patients from the experimental group in VS increased from 4.5 ± 0.33 to 8.7 ± 0.91 points (P < 0.001), for patients in MCS from 11.3 ± 1.0 to 18.2 ± 0.70 (P < 0.001) points. In the control group, scores of patients in VS rose from 4.3 ± 0.37 to 6.8 ± 0.49 (P < 0.001) points with the most significant changes in auditory and visual functions (P<0.001). In the control group of patients in MCS the oromotor function improved (P < 0.05), overall CRS-R scores changed insignificantly from 9.1 ± 0.57 to 10.1 ± 0.86 (P < 0.1). The best outcome (CRS-R > 19 points) was seen in patients from the experimental group [6 in VS (15.4 %) and 8 in MCS (31.8 %)]. In the control group, the best results did not exceed 10 points for the patents in VS, while 4 patients in MCS (21 %) reached 12–16 scores. During 30-day follow-up period of hospitalization after the SBH sessions mortality rate was 10 % (6 patients) in the experimental group and 21.6% (11 patients) in the control group.   Conclusion. Patients with CDC could benefit from serial SBH sessions performed as a part of comprehensive treatment and rehabilitation strategy. We suggest that selective reduction of frontal lobe temperature improves neurogenesis, neuronal regeneration, and neuroplasticity.   Цель исследования. Оценить перспективы клинического применения селективной гипотермии коры больших полушарий головного мозга (СГКМ) у пациентов с хроническими нарушениями сознания (ХНС).   Материал и методы. В пилотное открытое когортное исследование включили 111 пациентов с ХНС через 30 и более дней после церебральных катастроф (ишемический и геморрагических инсульты, травмы головного мозга). Критерии исключения: аноксические повреждения головного мозга (последствия длительной асистолии, асфиксии), активный септический процесс, нарушения сердечного ритма, исходная гипотермия (ниже 35,5 °С). Основную группу составили 60 пациентов: в вегетативном состоянии (ВС), n = 39 и в состоянии минимального сознания (СМС), n = 21. Группу сравнения — 51 пациент: в ВС, n = 32 и в СМС, n = 19. Пациентам основной группы выполнили 10 сеансов СГКМ длительностью 120 минут в период 14-и дней наблюдения. В обеих группах пациентам проводили стандартную медикаментозную нейротропную терапию и реабилитационные мероприятия. Пациентам группы сравнения СГКМ не проводили. Для индукции СГКМ охлаждали всю поверхность краниоцеребральной области головы с помощью шлемов-криоаппликаторов при температуре внутренней поверхности шлемов 3–7 °С. Контролировали температуру лобных отделов коры мозга при помощи неинвазивной СВЧ-радиотермометрии, регистрировали аксиальную температуру. Уровень сознания оценивали по шкале восстановления после комы «Coma Recovery Scale-Revised» (CRS-R, 2004 г.).   Результаты. Применение СГКМ позволило снизить температуру лобных отделов коры мозга на 2,4–3,1 °С без изменений аксиальной температуры. У пациентов основной группы выявили статистически значимый рост всех исследованных функций (слуховой, зрительной, двигательной, речевой, коммуникативной, бодрствования). Суммарный показатель вырос от 6,9 ± 0,6 до 12,1 ± 0,9 баллов (р < 0,001). У пациентов в ВС — от 4,5 ± 0,3 до 8,7 ± 0,9 баллов (р < 0,001), у пациентов в СМС — от 11,3 ± 1,0 до 18,2 ± 0,7 баллов (р < 0,001). В группе сравнения суммарный показатель вырос от 6,1 ± 0,5 до 8,1 ± 0,5 (р < 0,05). У пациентов в ВС суммарные данные возросли от 4,3 ± 0,4 до 6,8 ± 0,5 баллов (р < 0,001), причем наиболее значимо нарастали слуховая и зрительная функции (р < 0,001). У пациентов группы сравнения в СМС возросла речевая функция (р < 0,05), а суммарные показатели повысились незначительно от 9,1 ± 0,6 до 10,1 ± 0,9 баллов (р > 0,1). Лучшие результаты (CRS-R > 16 баллов) получили у пациентов основной группы: в ВС — у 6-и пациентов (15,4 %) и СМС — у 8-и (38,1 %). В группе сравнения у пациентов в ВС лучшие результаты по CRS-R не превышали 10 баллов, а у 4-х пациентов в СМС (21 %) на 14-ый день был достигнут уровень 12–16 баллов. При наблюдении в течение 30 дней после курса СГКМ летальность пациентов основной группы составила 6 пациентов (10 %), в группе сравнения — 11 пациентов (21,6 %).   Заключение. Применение курсов СГКМ у пациентов с ХНС в составе комплексных лечебно-реабилитационных мероприятий целесообразно. Высказали предположение, что селективное понижение температуры коры больших полушарий улучшает процессы нейрогенеза, нейрорегенерации и нейропластичности

Meglumine Sodium Succinate to Correct COVID-19-Associated Coagulopathy: the Feasibility Study

Aim of the study: to evaluate the effect of meglumine sodium succinate (MSS) on the efficacy of anticoagulant therapy in patients with severe COVID-19 infection complicated by bilateral community-acquired pneumonia.Materials and methods. Overall efficacy of treatment was analyzed in 12 patients hospitalized to ICU with the diagnosis of severe confirmed COVID-19 coronavirus infection (U07.1) complicated by bilateral multisegmental pneumonia. All patients received prophylactic anticoagulation with unfractionated heparin. The patients were divided into two groups: 7 of them received a multi-electrolyte solution containing MSS 5 ml/kg daily for the entire ICU stay (3-10 days) as a part of therapy; 5 patients received a similar volume of a conventional multi-electrolyte solution containing no metabolically active substrates and comprised a control group. Coagulation parameters were measured in arterial and venous blood of all patients at the following stages: 1) upon admission to the ICU; 2) 2-4 hours after the first dose of heparin; 3) 8-12 hours after the second dose of heparin; 4) 24 hours after the beginning of intensive therapy. On the 28th day of follow-up, mortality, duration of ICU stay, and incidence of thrombotic complications in the groups were evaluated. Nonparametric methods of statistical analysis were used to assess intragroup changes and intergroup differences.Results. The group of patients administered with MSS had significantly fewer thromboembolic events during 28 days of treatment and shorter ICU stay. These patients responded faster to anticoagulant therapy, which was suggested by more distinct changes in coagulation parameters, i.e. increased APTT, persisting viable thrombocyte population, reduced D-dimer and fibrinogen levels.Conclusion. The metabolic action of succinate possibly increases endothelial resistance to damaging factors and reduces its procoagulant activity. The hypothesis requires testing in a larger clinical study with a design including laboratory evaluation of the efficacy of varying doses of the studied drug as well as aiming at elucidation of the mechanisms of its effect on specific pro- and anticoagulation system components

Adaptive Phage Therapy in the Treatment of Patients with Recurrent Pneumonia (Pilot Study)

Aim. To evaluate the safety and efficacy of the adaptive phage therapy technique in patients with recurrent pneumonia in neurological critical care.Material and methods. The clinical study included 83 chronically critically ill patients with severe brain damage. The bacteriophage cocktail selected against specific hospital strains was administered by inhalation to 43 patients. The control group included 40 patients who received conventional antimicrobial therapy. The changes in clinical, laboratory and instrumental parameters, levels of biomarkers, microbiological and PCR tests of bronchoalveolar lavage fluid were assessed, including those in the «phage therapy with antibiotics» (n=29) and «phage therapy without antibiotics» (n=14) subgroups.Results. The groups were comparable in terms of basic parameters (age, sex, diagnosis, organ dysfunction according to APACHE II, use of vasoactive drugs) and the level of airway colonization with antibioticresistant bacterial strains. Good tolerability and absence of clinically significant side effects were observed during inhaled administration of the bacteriophage cocktail. Computed tomography on day 21 showed a significant reduction in lung damage in patients who received bacteriophages. Patients treated with bacteriophages without antibiotics had significantly lower need for mechanical ventilation. The mortality rate on day 28 did not differ significantly and was 4.7% (2/43) in the bacteriophage-treated group vs 5% (2/40) in the control group.Conclusion. The first experience of using the adaptive phage therapy technique in chronically critically ill patients in neurological intensive care demonstrated the safety of inhalational administration of the bacteriophage cocktail. The efficacy of the technique was confirmed by the treatment results obtained in the phage therapy group, which were not inferior to those in the group with conventional antibiotic therapy, while several clinical and laboratory parameters tended to improve even in patients who received bacteriophages and did not receive antibiotics

Адаптивная фаготерапия пациентов с рецидивирующими пневмониями (пилотное исследование)

Aim. To evaluate the safety and efficacy of the adaptive phage therapy technique in patients with recurrent pneumonia in neurological critical care.Material and methods. The clinical study included 83 chronically critically ill patients with severe brain damage. The bacteriophage cocktail selected against specific hospital strains was administered by inhalation to 43 patients. The control group included 40 patients who received conventional antimicrobial therapy. The changes in clinical, laboratory and instrumental parameters, levels of biomarkers, microbiological and PCR tests of bronchoalveolar lavage fluid were assessed, including those in the «phage therapy with antibiotics» (n=29) and «phage therapy without antibiotics» (n=14) subgroups.Results. The groups were comparable in terms of basic parameters (age, sex, diagnosis, organ dysfunction according to APACHE II, use of vasoactive drugs) and the level of airway colonization with antibioticresistant bacterial strains. Good tolerability and absence of clinically significant side effects were observed during inhaled administration of the bacteriophage cocktail. Computed tomography on day 21 showed a significant reduction in lung damage in patients who received bacteriophages. Patients treated with bacteriophages without antibiotics had significantly lower need for mechanical ventilation. The mortality rate on day 28 did not differ significantly and was 4.7% (2/43) in the bacteriophage-treated group vs 5% (2/40) in the control group.Conclusion. The first experience of using the adaptive phage therapy technique in chronically critically ill patients in neurological intensive care demonstrated the safety of inhalational administration of the bacteriophage cocktail. The efficacy of the technique was confirmed by the treatment results obtained in the phage therapy group, which were not inferior to those in the group with conventional antibiotic therapy, while several clinical and laboratory parameters tended to improve even in patients who received bacteriophages and did not receive antibiotics.Цель. Оценка безопасности и эффективности технологии адаптивной фаготерапии в лечении пациентов с рецидивирующими пневмониями в нейрореаниматологии.Материал и методы. В клиническое исследование включили 83 пациента в хроническом критическом состоянии с тяжелым повреждением головного мозга. У 43 пациентов ингаляционно применили комплексный препарат бактериофагов, адаптированный к госпитальным штаммам данного учреждения. Группу сравнения сравнения составили пациенты (n=40), получавшие традиционную антибактериальную терапию. Оценивали динамику клинико-лабораторных, инструментальных показателей, биомаркеров, результаты микробиологических и ПЦР-исследований бронхо-альвеолярного лаважа, в том числе — раздельно в подгруппах «фаготерапия с антибиотиками» (n=29) и «фаготерапия без антибиотиков» (n=14).Результаты. Группы были сопоставимы по основным показателям (возраст, пол, диагноз, степень органных дисфункций по APACHE II, применение вазоактивных препаратов) и уровню бактериальной колонизации дыхательных путей антибиотикорезистентными штаммами. При ингаляционном введении комплексного препарата бактериофагов наблюдали хорошую переносимость, отсутствие клинически значимых побочных эффектов. По данным компьютерной томографии, к 21-му дню выявили значимое снижение степени повреждения легких. У пациентов, получавших лечение бактериофагами без антибиотиков, значимо снизилась потребность в проведении искусственной вентиляции легких. Летальность к 28-м сут. значимо не различалась: при фаготерапии — 2/43 (4,7%), в группе сравнения — 2/40 (5%).Заключение. Первый опыт применения технологии адаптивной фаготерапии в лечении хронических реанимационных пациентов в нейрореаниматологии продемонстрировал безопасность ингаляционного введения комплексного препарата бактериофагов. Эффективность технологии подтверждена результатами лечения, полученными в группе фаготерапии, которые не уступали таковым в группе с традиционной антибиотикотерапией, а ряд клинико-лабораторных показателей имел тенденцию к улучшению даже в случаях полного отказа от антибиотиков в пользу бактериофагов

Исследование температурного баланса головного мозга методом микроволновой радиотермометрии (обзор)

Aim. This review aims to inform physicians of different specialties (anesthesiologists, intensivists, neurologists, neurosurgeons, oncologists) about the diagnostic capabilities of microwave radiothermometry, which enables to identify and analyze features of alterations of cerebral temperature in brain damage.The review displays a critical analysis of 80 recent Russian and foreign open access publications found by keywords.The review presents major clinical features and pathophysiological mechanisms of cerebral thermal balance disruptions in brain lesions. Slow responsiveness and vulnerability of cerebral thermal homeostasis regulation mechanisms that underlie development of different temperature heterogeneity levels in the cerebral cortex in healthy brain and brain lesions are highlighted. The authors postulate their concept about the critical role of hyperthermia in the pathogenesis of brain damage and disruption of interconnections in the global central regulation system. A body of evidence explaining direct association between the depth of consciousness impairment and degree of cerebral cortex temperature heterogeneity manifestation is presented. It is emphasized that a significant increase in temperature heterogeneity with areas of focal hyperthermia accompanies an acute period of ischemic stroke, while in post-comatose state usually associated with prolonged impairment of consciousness, the temperature heterogeneity significantly subsides. It has been suggested that lowering of an increased and rising of the reduced temperature heterogeneity, for example by using temperature exposure, can improve altered level of consciousness in patients with brain damage. The diagnostic capabilities of various technologies used for cerebral temperature measurement, including microwave radiothermometry (MWR), are evaluated. Data on high accuracy of MWR in measurement of the cerebral cortex temperature in comparison with invasive methods are presented.Conclusion. In healthy individuals MWR revealed a distinct daily rhythmic changes of the cerebral cortex temperature, and badly violated circadian rhythms in patients with brain lesions. Since MWR is an easy-toperform, non-invasive and objective diagnostic tool, it is feasible to use this technology to detect latent cerebral hyperthermia and assess the level of temperature heterogeneity disruption, as well as to study the circadian rhythm of temperature changes.Цель обзора. Информировать врачей различных специальностей (анестезиологов-реаниматологов, неврологов, нейрохирургов, онкологов) о диагностических возможностях микроволновой радиотермометрии, позволяющей выявлять и анализировать особенности нарушений церебрального теплового баланса при повреждениях головного мозга.Обзор содержит критический анализ информации 80 современных отечественных и зарубежных публикаций, находящихся в открытом доступе и найденных по ключевым словам.В обзоре привели основные сведения о клинико-патофизиологических особенностях нарушений церебрального теплового баланса при повреждениях головного мозга. Подчеркнули пассивность и уязвимость механизмов регуляции церебрального термогомеостаза, лежащих в основе развития различного уровня температурной гетерогенности коры больших полушарий в норме и при церебральных катастрофах. С патогенетических позиций постулировали концепцию о роли гипертермии в патогенезе повреждений головного мозга и процессах нарушения взаимосвязей в глобальных системах центральной регуляции. Привели доказательства связи между нарушением уровня сознания и степенью выраженности температурной гетерогенности коры больших полушарий. Подчеркнули, что существенное нарастание температурной гетерогенности с формированием очаговой гипертермии, сопровождает острейший период ишемического инсульта, а в посткоматозных состояниях, повлекших развитие длительного нарушения сознания, температурная гетерогенность значимо понижается. Высказали предположение о том, что снижение повышенной и повышение сниженной температурной гетерогенности, например, с использованием температурных воздействий на кору больших полушарий, способно улучшить показатели уровня сознания у пациентов с поражениями головного мозга. Дали оценку диагностических возможностей различных технологий измерения церебральной температуры, включая микроволновую радиотермометрию (РТМ). Привели данные о достаточно высокой точности РТМ при измерении температуры коры больших полушарий в сравнении с инвазивными способами регистрации температуры мозга.Заключение. С применением РТМ выявлена отчетливая суточная ритмика изменений температуры коры мозга у здоровых людей, грубо нарушающаяся при поражениях головного мозга. Поскольку РТМ является простым в исполнении, неинвазивным и объективным диагностическим инструментом, данную технологию целесообразно использовать в целях выявления скрыто протекающей церебральной гипертермии, для оценки уровня нарушения температурной гетерогенности, а также при исследовании циркадианной ритмики изменений температуры.

Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment

The community-wide GPCR Dock assessment is conducted to evaluate the status of molecular modeling and ligand docking for human G protein-coupled receptors. The present round of the assessment was based on the recent structures of dopamine D3 and CXCR4 chemokine receptors bound to small molecule antagonists and CXCR4 with a synthetic cyclopeptide. Thirty-five groups submitted their receptor-ligand complex structure predictions prior to the release of the crystallographic coordinates. With closely related homology modeling templates, as for dopamine D3 receptor, and with incorporation of biochemical and QSAR data, modern computational techniques predicted complex details with accuracy approaching experimental. In contrast, CXCR4 complexes that had less-characterized interactions and only distant homology to the known GPCR structures still remained very challenging. The assessment results provide guidance for modeling and crystallographic communities in method development and target selection for further expansion of the structural coverage of the GPCR universe. © 2011 Elsevier Ltd. All rights reserved

Two Birds with One Stone? Possible Dual-Targeting H1N1 Inhibitors from Traditional Chinese Medicine

The H1N1 influenza pandemic of 2009 has claimed over 18,000 lives. During this pandemic, development of drug resistance further complicated efforts to control and treat the widespread illness. This research utilizes traditional Chinese medicine Database@Taiwan (TCM Database@Taiwan) to screen for compounds that simultaneously target H1 and N1 to overcome current difficulties with virus mutations. The top three candidates were de novo derivatives of xylopine and rosmaricine. Bioactivity of the de novo derivatives against N1 were validated by multiple machine learning prediction models. Ability of the de novo compounds to maintain CoMFA/CoMSIA contour and form key interactions implied bioactivity within H1 as well. Addition of a pyridinium fragment was critical to form stable interactions in H1 and N1 as supported by molecular dynamics (MD) simulation. Results from MD, hydrophobic interactions, and torsion angles are consistent and support the findings of docking. Multiple anchors and lack of binding to residues prone to mutation suggest that the TCM de novo derivatives may be resistant to drug resistance and are advantageous over conventional H1N1 treatments such as oseltamivir. These results suggest that the TCM de novo derivatives may be suitable candidates of dual-targeting drugs for influenza.National Science Council of Taiwan (NSC 99-2221-E-039-013-)Committee on Chinese Medicine and Pharmacy (CCMP100-RD-030)China Medical University and Asia University (CMU98-TCM)China Medical University and Asia University (CMU99-TCM)China Medical University and Asia University (CMU99-S-02)China Medical University and Asia University (CMU99-ASIA-25)China Medical University and Asia University (CMU99-ASIA-26)China Medical University and Asia University (CMU99-ASIA-27)China Medical University and Asia University (CMU99-ASIA-28)Taiwan Department of Health. Clinical Trial and Research Center of Excellence (DOH100-TD-B-111-004)Taiwan Department of Health. Cancer Research Center of Excellence (DOH100-TD-C-111-005

On the possibility of using biologically active substances of aspen bark in brewing

The integrated use of aspen biomass can ensure the effective development of forestry and timber processing industries, reduce the share of waste. From the bark of aspen we obtained aqueous and water-alcohol extracts containing a complex of extractive substances possessing biological activity and representing practically all classes of organic compounds found in plants (vitamins, enzymes, proteins, fats, essential oils, etc.). As a raw material, a crushed aspen bark with a moisture content of 5% and an equivalent particle diameter of 2 mm was used. Extractants – water distilled and water-alcoholic solution 1:1. Extraction conditions: hydromodule– 10 g/g, temperature – 40°C, ultrasound frequency – 44 kHz. The effect of water-alcohol extracts on the fermentation of sucrose by beer yeast S-33 was studied. The expediency of using water-alcohol extract of aspen cortex at a dosage of 1% of the nutrient medium is shown. At the same time ferment activity of yeast increases, sugar consumption decreases by the side processes of fermentation, the economic coefficient showing the yield of ethanol from a unit of substrate is increased by 5,5% in comparison with the control. The kinetic characteristics of the fermentation process are calculated. The maximum specific growth rates of yeast and sugar consumption are observed when using water-alcohol extract of bark of aspen at a dosage of 1% and are 0,0052 h-1 and 0,049 g/(g-h), respectively. On the basis of the conducted studies, it can be concluded that the water-alcohol extract of the aspen bark should be used at a dosage of 1% of the nutrient medium. At the same time ferment activity of yeast increases, sugar consumption decreases by the side processes of fermentation, the economic coefficient showing the yield of ethanol from a unit of substrate is increased by 5,5% in comparison with the control. Industrial use of this extract in the production of beer will shorten the duration of the main fermentation for 1 day, increase the capacity of the fermentation unit and reduce the specific rates of energy consumption